Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 157
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...
Braxia Scientific Announces Board Appointment
Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...
HAVN Life Provides Corporate Update
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...
Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer...
PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK...
From Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan
Load more